
CMC Regulatory Considerations for Antibody-Drug Conjugates (ADCs) – From the Biologics Perspective
Speaker Presentation: Bioassays 2026
Zhang Lei, CDER, FDA, 2026
CMC Regulatory Considerations for Antibody-Drug Conjugates (ADCs) – From the Biologics Perspective